Li Jia, Sun Jianhua, Li Bing, Liu Zheli
Department of Ophthalmology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121000, P.R. China.
Department of Otorhinolaryngology, The Central Hospital of Jinzhou, Jinzhou, Liaoning 121000, P.R. China.
Exp Ther Med. 2018 Feb;15(2):1546-1551. doi: 10.3892/etm.2017.5565. Epub 2017 Nov 27.
The aim of the present study was to evaluate the efficacy of combination treatment with intravitreal ranibizumab (IVR) injection and photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV). A total of 64 patients with PCV were included in the present study, which were divided into the IVR monotherapy group (Group A) and combination treatment groups (Groups B-D) with different treatment intervals. All subjects were followed-up at 1, 3, 6 and 12 months following treatment, and subjected to the detection of best-corrected visual acuity (BCVA) and central foveal thickness (CFT). Compared with the monotherapy group, more significant BCVA improvement was observed for the combination treatment groups, with the most evident effect exhibited in Group C. At the end of the follow-up period, visual acuity improvement rates were markedly elevated in the combination treatment groups, as compared with the monotherapy group. According to optical coherence tomography, the CFT for the combination treatment groups was thinner than the monotherapy group. Among the combination groups, CFT improvement for Group C was superior to other groups. Fundus angiography demonstrated that, compared with monotherapy, combination treatment may significantly promote the regression and prevent the recurrence of polyps and BVN. The most efficient effectiveness was observed for Group C. In addition, combination treatment may significantly reduce the IVR injection numbers required to treat PCV. Patients receiving combination treatment with IVR injection and PDT have greater vision improvements, reduced macular degeneration and decreased injection numbers. Combination therapy may therefore, represent an effective and safe therapeutic strategy for PCV clinical treatment.
本研究的目的是评估玻璃体内注射雷珠单抗（IVR）联合光动力疗法（PDT）治疗息肉状脉络膜血管病变（PCV）的疗效。本研究共纳入64例PCV患者，分为IVR单药治疗组（A组）和不同治疗间隔的联合治疗组（B - D组）。所有受试者在治疗后1、3、6和12个月进行随访，并检测最佳矫正视力（BCVA）和中心凹厚度（CFT）。与单药治疗组相比，联合治疗组的BCVA改善更显著，C组效果最明显。随访期末，联合治疗组的视力改善率明显高于单药治疗组。根据光学相干断层扫描，联合治疗组的CFT比单药治疗组更薄。在联合治疗组中，C组的CFT改善优于其他组。眼底血管造影显示，与单药治疗相比，联合治疗可显著促进息肉和脉络膜新生血管（BVN）的消退并预防复发。C组观察到的疗效最显著。此外，联合治疗可显著减少治疗PCV所需的IVR注射次数。接受IVR注射联合PDT治疗的患者视力改善更大，黄斑变性减轻，注射次数减少。因此，联合治疗可能是PCV临床治疗的一种有效且安全的治疗策略。
